Menu Back to Measuring-Impact-in-Patient-Centered-Drug-Development

Overview

Stakeholders throughout the drug development enterprise have mobilized during the past decade to engage patients as partners through the implementation of patient-centric practices and initiatives. Professionals dedicated to supporting patient engagement within their organizations, however, have encountered and overcome a number of adoption and implementation challenges. Additionally, organizations are increasingly requiring quantifiable impact on drug development performance and economics to justify patient engagement investments.

This conference presents real world case studies and practical insights into successfully and effectively implementing practices and initiatives and measuring impact.

The Facilitating Adoption, Overcoming Resistance, and Measuring Impact of Patient-Centric Initiatives in Drug Development conference will begin with an overview of the current global environment for the patient engagement movement. Throughout the conference, sponsor companies will present lessons learned from their patient-centric initiatives and will share return on engagement metrics. Several panel discussions will also focus on actual experiences and ways that resistance and barriers to adoption were addressed and overcome. The evolution and growing influence of regulatory metrics will also be examined.


Exclusive Podcast!


Who should attend?

Professionals involved in:

  • Patient Advocacy/Engagement/Experience/Access (Including Chief Patient Officers)
  • Patient Communications
  • Medical Affairs and Medical Communications (Including Chief Medical Officers)
  • Health Outcomes
  • Study Endpoint Development
  • Clinical Trial Design and Optimization
  • Clinical Research
  • Clinical Operations
  • Benefit-Risk Assessment
  • Pharmacovigilance and Risk Management
  • Medical Science Liaisons
  • C-Suite Executives, Global Heads, Senior Directors, and Other Decision-Makers
  • Patient Support Services
  • Patient Organizations
  • Payers
  • Regulatory Agency Review

Learning objectives

At the conclusion of this activity, participants should be able to:
  • Implement patient centric initiatives more effectively
  • Measure the impact of their patient-centric initiatives
  • Benchmark their organization’s patient engagement maturity and experience
  • Anticipate and act on trends in the patient engagement movement
  • Evaluate the impact of current and evolving regulatory metrics on sponsor patient engagement practices

Program Committee

  • Mathieu  Boudes, PhD
    Mathieu Boudes, PhD PARADIGM Coordinator
    European Patients' Forum, France
  • Jeneen  Donadeo
    Jeneen Donadeo Program Director for Patient & PV
    Transcelerate, United States
  • Kenneth A. Getz, MBA
    Kenneth A. Getz, MBA Director of Sponsored Research Programs and Associate Professor
    Center For the Study of Drug Development, Tufts University School of Medicine, United States
  • Mary Jo  Lamberti, PhD, MA
    Mary Jo Lamberti, PhD, MA Associate Director of Sponsored Research, Research Assistant Professor
    Tufts Center for the Study of Drug Development, United States
  • Bennett  Levitan, MD, PhD
    Bennett Levitan, MD, PhD Senior Director, Benefit-Risk Assessment, Department of Epidemiology
    Janssen Research & Development, LLC, United States
  • Tjerk Jan  Schuitmaker, PhD, MSc
    Tjerk Jan Schuitmaker, PhD, MSc Assistant Professor
    Athena Institute of the Vrije University of Amsterdam , Netherlands
  • James E. Valentine, JD, MHS
    James E. Valentine, JD, MHS Attorney
    Hyman, Phelps & McNamara, PC, United States
Load More

Contact us

Registration Questions?

Send Email
1.888.257.6457


Exclusive Podcast!

The Patient’s Most Engaging Question: Why?

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download